Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × nilotinib × Dermatologic × Clear all

Phase

Status

Sponsor Class

OTHER 3 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 51 Myeloid 46 Sarcoma 11 Gastrointestinal 11 Lymphoid 7 Tumor-Agnostic 1 Dermatologic 1

Conditions

Interventions

pembrolizumab 157 Nivolumab 103 Ipilimumab 85 Dacarbazine 42 trametinib 35 3-ingenyl angelate 35 dabrafenib 31 Vemurafenib 28 cemiplimab 24 atezolizumab 21 Temozolomide 21 Imiquimod 21 binimetinib 19 Paclitaxel 18 cobimetinib 15 Aminolevulinic Acid 15 Cisplatin 14 Carboplatin 14 spartalizumab 13 avelumab 13 Fluorouracil 13 Cyclophosphamide 13 encorafenib 12 Gels 11 HhAntag691 10 Drug Therapy 10 Diclofenac 10 Bevacizumab 10 talimogene laherparepvec 9 relatlimab 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01028222 2015-12-30

TEAM

Novartis

Phase 2 Completed

55 enrolled 13 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡